![](https://monteverdelaw.com/wp-content/uploads/case-logo/prometheus-biosciences-inc.jpg)
Prometheus Biosciences, Inc. (NASDAQ: RXDX), relating to its proposed sale to Merck and Co. Under the terms of the agreement, RXDX shareholders are expected to receive $200.00 in cash per share they own.
Prometheus Biosciences, Inc. (NASDAQ: RXDX), relating to its proposed sale to Merck and Co. Under the terms of the agreement, RXDX shareholders are expected to receive $200.00 in cash per share they own.